ViGeneron GmbH

Industry

  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
See more in Biomedtracker

Latest on ViGeneron GmbH

Scrip

Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf

 
• By Joseph Haas and Vibha Ravi

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Jazz Moves Into IO With Engineered IFN⍺

Scrip

Biogen Reassessing Gene Therapy From Nightstar Deal After Phase II/III Miss

 
• By Joseph Haas

Biogen, Inc. reported that one of the ocular gene therapy candidates it acquired in its 2019 buyout of Nightstar Therapeutics plc missed its primary endpoint in a Phase II/III study, but said it vi

Scrip

Asia Deal Watch: Kyongbo To Supply Ceftobiprole API For Basilea

 
• By Joseph Haas, Jung Won Shin, and William Masters

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Kyongbo Inks Antibiotics CMO Pacts With

Scrip

Deal Watch: Deal Volume On The Rise Heading Into J.P. Morgan

 
• By Joseph Haas and Alex Shimmings

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Pfizer Links Up With Dewpoint Therapeut